OSU as Network Lead Academic Participating Site for the NCI NCTN

OSU 作为 NCI NCTN 网络主导学术参与网站

基本信息

批准号：
9025473
负责人：
CLARA D BLOOMFIELD
金额：
$ 138.46万
依托单位：
OHIO STATE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-05-06 至 2019-02-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9025473
关键词：
Address Adult Affect Ally American College of Radiology Imaging Network Area Basic Science Biochemistry Biological Markers Biomedical Research Biometry CEBPA gene Cancer Center Cancer Hospital Cancer Patient Chronic Myeloid Leukemia Clinic Clinical Clinical Research Clinical Sciences Clinical Trials Clinical Trials Network Comprehensive Cancer Center Contracts Cytotoxic agent Data Decitabine Development Discipline Disease Eastern Cooperative Oncology Group Education Enrollment Epidemiologist Faculty Fostering Funding Gastrointestinal Stromal Tumors Gene Expression Profiling Generations Genetic Goals Grant Gynecologic Oncology Gynecologic Oncology Group Health Health Personnel Hematologic Neoplasms Hematopoietic Neoplasms Histology Imatinib Immunology Individual Inpatients Knowledge Laboratory Research Laboratory Scientists Lead Leadership Malignant Neoplasms Measures Medical Medical Oncology Minority Modeling Molecular Genetics National Clinical Trials Network National Surgical Adjuvant Breast and Bowel Project Nurses Oblimersen Ohio Operative Surgical Procedures Outcome Outpatients Pathologist Patient-Focused Outcomes Patients Peer Review Pentostatin Performance Pharmacists Pharmacodynamics Pharmacology Phase Physicians Postdoctoral Fellow Protocols documentation Psychiatrist Quality of life Radiation Radiation Oncologist Radiation Therapy Oncology Group Radio Rare Diseases Research Research Activity Research Design Research Infrastructure Research Personnel Resources Risk Science Scientist Site Solid Neoplasm Southwest Oncology Group Structure Surgical Oncologist Surgical Oncology Symptoms TNFRSF5 gene Testing Therapeutic Therapeutic Agents Therapeutic Index Tissues Toxic effect Training Translating Translational Research Translational trial Tumor Biology Universities base bcr-abl Fusion Proteins cancer prevention career development college design disorder subtype doctoral student improved improved outcome learning network lenalidomide leukemia meetings member new technology next generation next generation sequencing novel novel therapeutics phase 1 study phase 3 study pre-clinical preclinical study programs research study rituximab sound stem success targeted treatment treatment trial tumor heterogeneity

项目摘要

DESCRIPTION (provided by applicant): Faculty from The Ohio State University (OSU) are integrated into the scientific and administrative activities, participate in meetings, manage multiple core labs, design studies and enroll patients in all existing adult NCTN network groups using cancer center resources to leverage group resources. OSU investigators develop and lead studies designed to enroll patients on multi-disciplinary treatment trials as well as develop and perform correlative science related research studies, bringing special expertise in hematologic malignancies and solid tumors. Our medical, hematologic, surgical and radiation oncologists, trans planters, psychiatrists, pathologists, cytogeneticists, translational and basic laboratory scientists, statisticians, epidemiologists, nurses, pharmacists, and clinical research coordinators help to frame the clinical and basic science questions whose answers contribute to improved patient outcomes and to understanding tumor biology. The goal of this application is to provide the infrastructure to support OSU's participation in the scientific and clinical research activities of the NCI's NCTN Program as a Network Lead Academic Participating Site (NLAPS). We will use the support to make scientific discoveries about tumor biology, find better treatments and augment the quality of life for patients thus improving outcomes across the spectrum of cancers affecting adults. This comprehensive program aims to: 1) Investigate new therapeutic agents, and their toxicities in Phase I to 1 clinical trials; 2) Evaluate the efficacy nd toxicity of novel combinations based on preclinical data to exploit synergistic combinations more effectively; 3) Develop multi-modal approaches using surgical, immunological, and radio therapeutic measures in optimal combinations; 4) Integrate experts in molecular genetics, biochemistry, pharmacology, immunology, and biostatistics in the design and execution of therapeutic protocols; 5) Improve cancer outcomes through discovery and education of pre and post-doctoral students, nurses, allied medical personnel and physicians, 6) Understand and exploit tumor heterogeneity to fully exploit the value of targeted therapies, 7) Improve the management of cancer related symptoms, and 8) enroll patients on trials.

描述（由申请人提供）：俄亥俄州立大学 (OSU) 的教员融入科学和行政活动、参加会议、管理多个核心实验室、设计研究并利用癌症中心资源将患者纳入所有现有成人 NCTN 网络小组发挥集团资源优势。俄勒冈州立大学的研究人员开发和领导旨在招募患者参加多学科治疗试验的研究，以及开发和执行相关的科学相关研究，带来血液恶性肿瘤和实体瘤方面的特殊专业知识。我们的医学、血液学、外科和放射肿瘤学家、移植医师、精神病学家、病理学家、细胞遗传学家、转化和基础实验室科学家、统计学家、流行病学家、护士、药剂师和临床研究协调员帮助构建临床和基础科学问题，这些问题的答案有助于改善患者的治疗效果并了解肿瘤生物学。此应用程序的目标是提供基础设施，以支持 OSU 作为网络主导学术参与站点 (NLAPS) 参与 NCI NCTN 计划的科学和临床研究活动。我们将利用这些支持对肿瘤生物学进行科学发现，找到更好的治疗方法并提高患者的生活质量，从而改善影响成人的各种癌症的治疗结果。该综合计划旨在： 1) 在 I 期至 1 期临床试验中研究新的治疗药物及其毒性； 2）根据临床前数据评估新组合的疗效和毒性，以更有效地开发协同组合； 3) 开发多模式方法，以最佳组合使用手术、免疫和放射治疗措施； 4）整合分子遗传学、生物化学、药理学、免疫学和生物统计学方面的专家来设计和执行治疗方案； 5) 通过博士前和后学生、护士、专职医务人员和医生的发现和教育来改善癌症结果，6) 了解和利用肿瘤异质性，以充分发挥靶向治疗的价值，7) 改善癌症相关症状的管理和 8) 招募患者参加试验。